Drugs / sodium selenite
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04296578 | Oct 2020 → Oct 2022 | castration-resistant prostate carcinoma | Stanford University | Withdrawn | No outcome recorded |
| Phase 1 | NCT02184533 | Jul 2014 → May 2018 | hormone-resistant prostate carcinoma, plasma cell myeloma, plasmacytoma, prostate adenocarcinoma | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT01155791 | Apr 2010 → Oct 2012 | prostate cancer, urinary system neoplasm | Sandy Srinivas | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01959438 | Feb 2007 → Oct 2016 | refractory malignant neoplasm | Karolinska University Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00188604 | Jan 2004 → Jan 2009 | breast neoplasm, lymphedema | University Health Network, Toronto | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 2 | NCT01390506 Comparator | Jan 2017 → Jul 2018 | cardiac arrest | Medical University of Graz | Withdrawn | No outcome recorded |
| Phase 3 | NCT02530788 Comparator | Aug 2015 → Jul 2017 | left ventricular failure | RWTH Aachen University | Completed | No outcome recorded |
| Phase 3 | NCT02002247 Comparator | Jan 2015 → Feb 2021 | heart disorder | Daren K. Heyland | Unknown | No outcome recorded |
| Phase 3 | NCT01141556 Comparator | Dec 2010 → Jul 2012 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 3 | NCT00832039 Comparator | Nov 2009 → Mar 2013 | infectious disease with sepsis | Competence Network Sepsis | Completed | No outcome recorded |
| Phase 3 | NCT01442727 Comparator | Dec 2006 → Apr 2009 | hyperpigmentation of the skin, keratosis, poisoning | Texas Tech University | Completed | No outcome recorded |
| Phase 4 | NCT03081949 Comparator | Jun 2017 → Jun 2019 | peripartum cardiomyopathy | Aminu Kano Teaching Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sodium selenite | “Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer” NCT01155791 ↗11“intravenous bolus of 4000 μg selenium (in the form of sodium selenite) or placebo” PMID 28502744 ↗ May 2017 |
| Known as | Selenase | “Effects of High-dose Intravenous Selenium (Selenase®) on the Systemic Inflammatory Response Syndrome and Related Organ Dysfunction” NCT01141556 ↗ |
| Known as | Selenium Supplement | “Selenium Supplement (sodium selenite)” NCT02530788 ↗ |
| Action | Inhibit | “Selenite is a potential novel inhibitor of AR expression and function in prostate cancer.” NCT01155791 ↗ |
| Route | Intravenous | “The selenium group receives sodium selenite intravenously” NCT00832039 ↗ |
| Target | AR | “Selenite is a potential novel inhibitor of AR expression and function in prostate cancer.” NCT01155791 ↗ |